You're reading the free version. Trader adds the live tape and alerts.
Start tracking
AVTX Sale Disclosure
Sullivan Christopher Ryan · SEC Form 4 · Filed Sep 18, 2026
Sale
Calculated transaction value
$202.44K
Sullivan Christopher Ryan Chief Financial Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Sep 16, 2026
Public filing date
Sep 18, 2026
Filing lag
Filed 2 days later
AVTX daily price context
Close on/before transaction
$16.58
Sep 16, 2026
First close after public filing
$16.17
Sep 21, 2026
30-day return after filing
-28.32%
Through Oct 19, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 12,394 shares @ $16.33
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001810417-26-000023
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$324.89K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX | Exercise | Sep 16, 2026 | $122.45K |
| Avalo Therapeutics, Inc. AVTX Current | Sale | Sep 16, 2026 | $202.44K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Sep 16, 2026 | $0 |